<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Brekenfeld C</dc:creator>
  <dc:creator>Gralla J</dc:creator>
  <dc:creator>Mattle HP</dc:creator>
  <dc:creator>El-Koussy M</dc:creator>
  <dc:creator>Schroth G</dc:creator>
  <dc:date>2009</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Intravenous thrombolysis (IVT) is the evidence-based treatment of acute ischemic stroke in the first 3 h after symptom onset (IVT 3-4.5 h: off-label use with informed consent of the patient). However, intra-arterial thrombolysis (IAT) results in higher recanalization rates of the middle cerebral artery compared to IVT. Therefore it seems reasonable to apply IAT in addition or instead of IVT up to 6 h after symptom onset.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/286194</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s00117-008-1773-z</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/19271207</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Der Radiologe. - 2009</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Fibrinolytic Agents</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Infarction, Middle Cerebral Artery</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Thrombolytic Therapy</dc:subject>
  <dc:title xmlns:ns5="xml" ns5:lang="en">[Thrombolysis of the middle cerebral artery].</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
